315 related articles for article (PubMed ID: 28223031)
1. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
Crespo-Facorro B; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Valdizan EM; Pérez-Iglesias R; Amado-Señaris JA; Teresa Garcia-Unzueta M; Labad J; Correll C; Ayesa-Arriola R
Schizophr Res; 2017 Nov; 189():134-141. PubMed ID: 28223031
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Crespo-Facorro B; Ortiz-García de la Foz V; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Vázquez-Barquero JL; Pérez-Iglesias R
Schizophr Res; 2013 Jul; 147(2-3):375-82. PubMed ID: 23643328
[TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Pérez-Iglesias R; Ortiz-Garcia de la Foz V; Martínez García O; Amado JA; Garcia-Unzueta MT; Ayesa-Arriola R; Suarez-Pinilla P; Tabares-Seisdedos R; Crespo-Facorro B
Schizophr Res; 2014 Oct; 159(1):90-4. PubMed ID: 25151200
[TBL] [Abstract][Full Text] [Related]
4. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
[TBL] [Abstract][Full Text] [Related]
5. Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.
Crespo-Facorro B; de la Foz VO; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Martinez-Garcia O; Pérez-Iglesias R
Psychopharmacology (Berl); 2014 Jan; 231(2):357-66. PubMed ID: 23958945
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
[TBL] [Abstract][Full Text] [Related]
8. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
Vázquez-Bourgon J; Ibáñez Alario M; Mayoral-van Son J; Gómez Revuelta M; Ayesa Arriola R; Juncal Ruiz M; Ortiz-García de la Foz V; Crespo Facorro B
Eur Neuropsychopharmacol; 2020 Oct; 39():46-55. PubMed ID: 32891516
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Ortiz-García de la Foz V; Vázquez-Bourgon J; González-Pinto A; Crespo-Facorro B
Int J Neuropsychopharmacol; 2018 Dec; 21(12):1090-1101. PubMed ID: 30215723
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B
Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576
[TBL] [Abstract][Full Text] [Related]
11. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Morlán-Coarasa MJ; Arias-Loste MT; Ortiz-García de la Foz V; Martínez-García O; Alonso-Martín C; Crespo J; Romero-Gómez M; Fábrega E; Crespo-Facorro B
Psychopharmacology (Berl); 2016 Dec; 233(23-24):3947-3952. PubMed ID: 27620899
[TBL] [Abstract][Full Text] [Related]
12. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
[TBL] [Abstract][Full Text] [Related]
14. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
15. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
16. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Park Y; Hernandez-Diaz S; Bateman BT; Cohen JM; Desai RJ; Patorno E; Glynn RJ; Cohen LS; Mogun H; Huybrechts KF
Am J Psychiatry; 2018 Jun; 175(6):564-574. PubMed ID: 29730938
[TBL] [Abstract][Full Text] [Related]
17. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
[TBL] [Abstract][Full Text] [Related]
19. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
20. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Rajagopalan K; Wade S; Meyer N; Loebel A
Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
